Highlights

  • Governance approval received from Monash Health for the HARNESS-1 Phase 1 trial of RC220 in EGFR non-small cell lung cancer patients treated with osimertinib.
  • Trial targets a significant unmet need by aiming to prevent or delay resistance to EGFR-mutant tyrosine kinase inhibitors.
  • RC220 positioned as a potential complementary therapy alongside standard-of-care treatment.
  • RAC share price has trading above horizontal trendline support.

Racura Oncology Ltd (ASX: RAC) has received governance approval from Monash Health for its Phase 1 clinical trial evaluating RC220 (E,E-bisantrene) in combination with osimertinib (Tagrisso®, AstraZeneca) in patients with EGFR-mutated non-small cell lung cancer (NSCLC). The study will assess safety, tolerability, and pharmacokinetics (PK) of the combination therapy. Notably, human ethics approval for the trial had already been granted in November 2025, marking another key step forward in the company’s clinical development program.

Racura Oncology in Focus: Approval Boosts Investor Interest

Racura Oncology Ltd announced that its Principal Scientist, Dr. Rodney Cusack, confirmed governance approval enables the company to advance the RC220 clinical trial in EGFR-mutated NSCLC patients, ensuring required infrastructure and oversight are in place. The study targets resistance pathways to osimertinib using RC220’s RNA and DNA G4 binding mechanism. Trial initiation activities, including site training at Monash Medical Centre, are scheduled for March 2026, paving the way for patient recruitment.

The HARNESS-1 Phase 1a/b trial will use ctDNA screening, followed by dose escalation and expansion stages to determine safety, pharmacokinetics, and optimal dosing. The study will also evaluate key outcomes such as progression-free survival, overall survival, and molecular response markers.

RAC Holds Support: Can the Uptrend Sustain?

From a technical standpoint, RAC has managed to sustain above its horizontal trendline support, indicating underlying strength in price action. This level continues to act as a reliable support zone, helping the stock stabilize after recent volatility. As long as RAC holds above this key threshold, the broader bullish structure is likely to remain intact, keeping the possibility of a continued upward move or recovery in the near term.

RAC continues to trade below its 50-period SMA, indicating near-term resistance and limited upside momentum. However, the 14-period RSI at 52.13 reflects strong buying interest and sustained positive momentum. On the upside, key resistance levels are seen around AUD 2.55 and AUD 2.80, which may act as important supply zones and could cap further gains unless decisively breached.

Bullish Bias Firm as Critical Support Holds

Racura Oncology Ltd (ASX: RAC) outlook remains cautiously positive, supported by recent clinical trial approval and improving technical structure. While strong RSI indicates buying interest and support levels remain intact, the stock faces near-term resistance below key moving averages. A breakout above resistance is crucial to sustain further upside momentum.